^
Association details:
| Biomarker: | FBXW7 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
472P - Whole genome sequencing of metastatic CRC reveals footprints from the past and present with future clinical relevance
Published date:
09/14/2020
Excerpt:
In addition to KRAS/NRAS and BRAF, mutations in FBXW7 were associated with poor response to EGFR-targeted treatments.
Trial ID:
